AstraZeneca Competitors

ZEG Stock

127.55 1.10 0.87%

AstraZeneca PLC competes with DAIRY FARM, Aluminumof China, Titan Machinery, TITAN MACHINERY, and Sterling Construction; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers-General industry. Analyzing AstraZeneca PLC competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of AstraZeneca PLC to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out AstraZeneca PLC Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of AstraZeneca PLC competition on your existing holdings.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of AstraZeneca PLC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.

Hype

Prediction

Low	Estimated	High
124.86	126.45	128.04

Details

Intrinsic

Valuation

Low	Real	High
119.80	121.39	139.10

Details

AstraZeneca PLC Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between AstraZeneca PLC and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of AstraZeneca and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of AstraZeneca PLC does not affect the price movement of the other competitor.

	DFA1	AOC	3TY	3TY	UAO	4D7	M0G
DFA1		0.34	0.78	0.79	0.87	-0.41	0.11	DFA1
AOC	0.34		0.29	0.29	0.21	-0.28	0.72	AOC
3TY	0.78	0.29		1.0	0.88	-0.13	0.13	3TY
3TY	0.79	0.29	1.0		0.88	-0.13	0.13	3TY
UAO	0.87	0.21	0.88	0.88		-0.12	-0.01	UAO
4D7	-0.41	-0.28	-0.13	-0.13	-0.12		-0.27	4D7
M0G	0.11	0.72	0.13	0.13	-0.01	-0.27		M0G
	DFA1	AOC	3TY	3TY	UAO	4D7	M0G

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

3TY	+ 1.0	3TY
UAO	+ 0.88	3TY
UAO	+ 0.88	3TY
UAO	+ 0.87	DFA1
3TY	+ 0.79	DFA1
3TY	+ 0.78	DFA1

High negative correlations

4D7	- 0.41	DFA1
4D7	- 0.28	AOC
M0G	- 0.27	4D7
4D7	- 0.13	3TY
4D7	- 0.13	3TY
4D7	- 0.12	UAO

Risk-Adjusted Indicators

There is a big difference between AstraZeneca Stock performing well and AstraZeneca PLC Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze AstraZeneca PLC's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
DFA1	1.69	0.51	0.26	4.70	1.15	(2.45)	4.43	(1.94)	15.86
AOC	3.07	0.39	0.07	0.63	3.98	(3.74)	6.56	(6.35)	19.64
3TY	2.09	0.07	0.10	0.12	1.77	(3.46)	5.79	(3.20)	18.48
3TY	2.05	0.07	0.10	0.11	1.79	(3.27)	5.47	(3.20)	18.48
UAO	2.32	0.53	0.32	0.42	1.38	(3.26)	7.12	(2.88)	18.96
4D7	0.93	0.01	(0.05)	1.12	1.17	(1.30)	1.87	(1.89)	5.77
M0G	2.30	0.08	0.03	0.18	2.38	(2.70)	3.49	(4.40)	15.21

Unable to evaluate fundamental data of [DFA1.STU, AOC.F, 3TY.F, 3TY.BE, UAO.F, 4D7.F, M0G.F] at this time. Please try again later

All Fundamental Data

AstraZeneca PLC Competitive Analysis

The better you understand AstraZeneca PLC competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, AstraZeneca PLC's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across AstraZeneca PLC's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	ZEG	DFA1	AOC	3TY	3TY	UAO	4D7	M0G
	0.87 127.55 AstraZeneca	0.92 2.20 DAIRY	1.82 0.54 Aluminumof	2.04 14.40 Titan	2.78 14.00 TITAN	1.88 171.80 Sterling	1.80 109.00 Daito	1.06 0.95 FIREWEED
Market Volatility (90 Days Market Risk)	Very steady	Relatively risky	Out of control	Not too volatile	Not too volatile	Very steady	Very steady	Dangerous
Market Performance (90 Days Performance)	Very Weak	Good	OK	OK	OK	Good	Very Weak	Modest
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Low	Low	Low	Low	Low	Low	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Over Valued	Fairly Valued	Fairly Valued	Under Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Cautious Hold	Strong Buy	Strong Sell	Strong Hold	Strong Hold	Strong Buy	Strong Sell	Sell
Current Ratio	N/A	N/A	0.78 X	1.39 X	N/A	1.66 X	1.62 X	N/A
Net Asset	96.48 B	7.6 B	192.38 B	946.67 M	946.67 M	1.44 B	1.01 T	N/A
Profit Margin	0.07 %	N/A	0.02 %	0.05 %	N/A	0.06 %	0.04 %	N/A
EBITDA	9.33 B	N/A	22.62 B	114.75 M	114.75 M	212.82 M	120.72 B	N/A
Operating Margin	0.20 %	N/A	0.06 %	0.07 %	N/A	0.09 %	0.05 %	N/A
Current Valuation	228.75 B	7.4 B	18.17 B	1.22 B	1.22 B	1.25 B	5.67 B	N/A
Price To Book	6.14 X	3.76 X	0.84 X	1.79 X	1.79 X	2.18 X	2.46 X	N/A
Five Year Return	N/A	N/A	N/A	N/A	N/A	N/A	3.11 %	N/A
Beta	0.19	N/A	2.33	1.68	N/A	1.41	0.38	N/A
Number Of Employees	83.5 K	N/A	60.06 K	2.29 K	13	7	17.65 K	N/A
Shares Outstanding	1.55 B	N/A	3.94 B	22.71 M	N/A	30.33 M	68.19 M	N/A
Cash Flow From Operations	9.81 B	N/A	28.31 B	158.92 M	158.92 M	219.12 M	112.48 B	N/A
Annual Yield	0.02 %	0.01 %	0.01 %	N/A	N/A	N/A	0.04 %	N/A
Total Debt	22.96 B	310.8 M	52.49 B	74.77 M	74.77 M	398.74 M	81.63 B	N/A
Return On Equity	0.0863	N/A	0.0845	0.23	N/A	0.24	0.16	N/A
Z Score	4.8	6.6	1.0	8.8	6.4	2.2	1.0	N/A
Return On Asset	0.0555	N/A	0.0535	0.0902	N/A	0.0752	0.0561	N/A
Book Value Per Share	23.90 X	N/A	3.66 X	22.83 X	N/A	15.65 X	5,701 X	N/A
Total Asset	96.48 B	7.6 B	192.38 B	946.67 M	946.67 M	1.44 B	1.01 T	N/A
Last Dividend Paid	2.9	N/A	0.032	N/A	N/A	N/A	275.0	N/A
Debt To Equity	N/A	N/A	155.10 %	170.40 %	N/A	55.80 %	33.30 %	N/A
Target Price	N/A	N/A	N/A	37.33	N/A	28.0	N/A	N/A
Shares Owned By Institutions	47.60 %	N/A	28.07 %	83.32 %	N/A	83.59 %	42.79 %	N/A
Market Capitalization	194.87 B	3.58 B	12.43 B	1 B	676.92 M	1.1 B	6.06 B	N/A
Price To Earnings To Growth	1.36 X	N/A	N/A	N/A	N/A	0.53 X	N/A	N/A
Price To Earning	N/A	N/A	22.45 X	32.46 X	N/A	11.86 X	10.55 X	N/A
Price To Sales	4.41 X	0.43 X	0.04 X	0.42 X	0.42 X	0.47 X	0 X	N/A
Net Income	2.5 B	N/A	5.08 B	66.05 M	66.05 M	106.46 M	69.58 B	N/A
Earnings Per Share	2.00 X	N/A	0.04 X	4.56 X	N/A	2.78 X	6.04 X	N/A
Shares Owned By Insiders	0.22 %	N/A	4.53 %	11.13 %	N/A	3.80 %	12.88 %	N/A
Revenue	44.35 B	N/A	269.75 B	1.71 B	1.71 B	1.77 B	1.58 T	N/A
Cash And Equivalents	N/A	N/A	3.75 B	63.33 M	N/A	56.76 M	2.11 B	N/A
Cash Per Share	N/A	N/A	0.23 X	2.90 X	N/A	2.15 X	28.47 X	N/A
Gross Profit	35.73 B	N/A	27.6 B	332.72 M	N/A	274.57 M	260.14 B	N/A
Day Typical Price	127.62	2.2	0.54	14.4	14.0	172.5	109.0	0.95
Accumulation Distribution	92.6	N/A	N/A	N/A	N/A	0.0121	N/A	N/A
Market Facilitation Index	1.0E-4	N/A	N/A	N/A	N/A	2.1	N/A	N/A
Daily Balance Of Power	0.8462	9.2 T	(9,223,372,036,855)	(9,223,372,036,855)	(9,223,372,036,855)	(1.57)	(9,223,372,036,855)	9.2 T
Period Momentum Indicator	1.1	0.02	(0.01)	(0.30)	(0.40)	(3.30)	(2.00)	0.01
Rate Of Daily Change	1.01	1.01	0.98	0.98	0.97	0.98	0.98	1.01
Day Median Price	127.65	2.2	0.54	14.4	14.0	172.85	109.0	0.95
Price Action Indicator	0.45	0.01	(0.01)	(0.15)	(0.20)	(2.70)	(1.00)	0.005
Coefficient Of Variation	(1,021)	458.0	918.81	877.54	862.41	502.67	5803.06	1676.67
Mean Deviation	1.02	1.69	3.07	2.09	2.05	2.32	0.9271	2.3
Jensen Alpha	(0.18)	0.5065	0.3889	0.0742	0.0673	0.5251	0.0111	0.0824
Total Risk Alpha	(0.36)	0.2168	(0.08)	(0.04)	(0.03)	0.2447	(0.15)	(0.20)
Sortino Ratio	N/A	0.2616	0.0673	0.0997	0.0973	0.3245	(0.05)	0.0287
Downside Variance	N/A	2.66	29.15	5.3	5.48	3.18	2.85	6.83
Standard Deviation	1.59	2.41	4.26	2.89	2.83	3.41	1.28	2.94
Kurtosis	9.45	5.23	1.83	2.86	3.13	5.4	1.1	1.8
Potential Upside	1.74	4.43	6.56	5.79	5.47	7.12	1.87	3.49
Treynor Ratio	(0.94)	4.7	0.6319	0.1174	0.1143	0.42	1.12	0.1798
Maximum Drawdown	9.85	15.86	19.64	18.48	18.48	18.96	5.77	15.21
Variance	2.52	5.81	18.14	8.37	8.0	11.63	1.64	8.62
Market Risk Adjusted Performance	(0.93)	4.71	0.6419	0.1274	0.1243	0.43	1.13	0.1898
Risk Adjusted Performance	(0.07)	0.1653	0.0872	0.0901	0.0915	0.1521	0.0168	0.0508
Skewness	(1.79)	1.68	(0.29)	1.12	1.08	2.06	(0.42)	0.8513
Semi Deviation	N/A	1.15	3.98	1.77	1.79	1.38	1.17	2.38
Information Ratio	(0.16)	0.1768	0.0853	0.0793	0.0806	0.1696	(0.06)	0.0256
Value At Risk	(2.57)	(1.94)	(6.35)	(3.20)	(3.20)	(2.88)	(1.89)	(4.40)
Expected Short fall	N/A	(2.45)	(3.74)	(3.46)	(3.27)	(3.26)	(1.30)	(2.70)
Downside Deviation	N/A	1.63	5.4	2.3	2.34	1.78	1.69	2.61
Semi Variance	N/A	1.33	15.81	3.12	3.19	1.91	1.37	5.68

AstraZeneca PLC Competition Performance Charts

Five steps to successful analysis of AstraZeneca PLC Competition

AstraZeneca PLC's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by AstraZeneca PLC in relation to its competition. AstraZeneca PLC's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of AstraZeneca PLC in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact AstraZeneca PLC's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to AstraZeneca PLC, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your AstraZeneca PLC position

In addition to having AstraZeneca PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Insurance Thematic Idea Now

Insurance

Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.

View All Next

Launch

Additional Tools for AstraZeneca Stock Analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC